Literature DB >> 10987739

Treatment of tularemia with ciprofloxacin.

A Chocarro, A Gonzalez, I Garcia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10987739     DOI： 10.1086/313946

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis.

Authors:  Luke C Kingry; Ryan M Troyer; Nicole L Marlenee; Helle Bielefeldt-Ohmann; Richard A Bowen; Alan R Schenkel; Steven W Dow; Richard A Slayden
Journal:  Microbes Infect       Date:  2010-11-09       Impact factor: 2.700

2.  Ciprofloxacin: Tularemia (Adults).

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2015-04-08

3.  Francisella tularensis: a red-blooded pathogen.

Authors:  J Wayne Conlan
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

4.  A case of tularemia after an endurance run in a non-endemic region.

Authors:  R Meckenstock; A Therby; A Le Monnier; D Khau; S Monnier; B Pangon; A Greder-Belan
Journal:  Infection       Date:  2012-10-17       Impact factor: 3.553

5.  Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.

Authors:  Karleigh A Hamblin; Stuart J Armstrong; Kay B Barnes; Carwyn Davies; Jonathan P Wong; James D Blanchard; Sarah V Harding; Andrew J H Simpson; Helen S Atkins
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

6.  Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections.

Authors:  Jasmin Chen; Fang-Yi Su; Debobrato Das; Selvi Srinivasan; Hye-Nam Son; Brian Lee; Frank Radella; Dale Whittington; Taylor Monroe-Jones; T Eoin West; Anthony J Convertine; Shawn J Skerrett; Patrick S Stayton; Daniel M Ratner
Journal:  Biomaterials       Date:  2018-10-16       Impact factor: 12.479

7.  Effect of induced pyrexia on the disposition kinetics of ciprofloxacin in dogs.

Authors:  Faqir Muhammad; Masood Akhtar; M Irfan Anwar; M Javed Arshed
Journal:  Vet Res Commun       Date:  2009-09-02       Impact factor: 2.459

Review 8.  Development of Liposomal Ciprofloxacin to Treat Lung Infections.

Authors:  David Cipolla; Jim Blanchard; Igor Gonda
Journal:  Pharmaceutics       Date:  2016-03-01       Impact factor: 6.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.